Diogo Alpuim Costa

Dr. Diogo Alpuim Costa

CUF Oncologia, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
JNJosé Guilherme Nobre
José Guilherme Nobre
MBMarta Vaz Batista
Marta Vaz Batista
CRCatarina Ribeiro
Catarina Ribeiro
CCCatarina Calle
Catarina Calle
LCLuís Costa
Luís Costa
Breast cancer (BC) is the most common malignancy and the second cause of cancer-specific death in women from high-income countries. Recently, gut microbiota dysbiosis emerged as a key player that may directly and/or indirectly influence development, treatment, and prognosis of BC through diverse biological processes: host cell proliferation and death, immune system function, chronic inflammation, oncogenic signalling, hormonal and detoxification pathways. Gut colonisation occurs during the prenatal period and is later diversified over distinct phases throughout life. In newly diagnosed postmenopausal BC patients, an altered faecal microbiota composition has been observed compared with healthy controls. Particularly, β-glucuronidase bacteria seem to modulate the enterohepatic circulation of oestrogens and their resorption, increasing the risk of hormone-dependent BC. Moreover, active phytoestrogens, short-chain fatty acids, lithocholic acid, and cadaverine have been identified as bacterial metabolites influencing the risk and prognosis of BC. As in gut, links are also being made with local microbiota of tumoural and healthy breast tissues. In breast microbiota, different microbial signatures have been reported, with distinct patterns per stage and biological subtype. Total bacterial DNA load was lower in tumour tissue and advanced-stage BC when compared with healthy tissue and early stage BC, respectively. Hypothetically, these findings reflect local dysbiosis, potentially creating an environment that favours breast tumour carcinogenesis (oncogenic trigger), or the natural selection of microorganisms adapted to a specific microenvironment. In this review, we discuss the origin, composition, and dynamic evolution of human microbiota, the links between gut/breast microbiota and BC, and explore the potential implications of metabolomics and pharmacomicrobiomics that might impact BC development and treatment choices toward a more personalised medicine. Finally, we put in perspective the potential limitations and biases regarding the current microbiota research and provide new horizons for stronger accurate translational and clinical studies that are needed to better elucidate the complex network of interactions between host, microorganisms, and drugs in the field of BC.

30 May 2016 in Head & Neck
Verified
Journal Article
Closed access
PDF file
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
TCTiago Porfírio Costa
Tiago Porfírio Costa
ENEduardo Carlinhos Netto
Eduardo Carlinhos Netto
NJNatércia Joaquim
Natércia Joaquim
IVIsabel Ventura
Isabel Ventura
AMAntónio Rita Moreira
António Rita Moreira

28 January 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
MVMarina Vitorino
Marina Vitorino
SASusana Baptista de Almeida
Susana Baptista de Almeida
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
AFAna Faria
Ana Faria
CCConceição Calhau
Conceição Calhau
SBSofia Azambuja Braga
Sofia Azambuja Braga
Breast cancer (BC) is the most common malignancy and the second cause of cancer-specific death in women from high-income countries. Infectious agents are the third most important risk factor for cancer incidence after tobacco and obesity. Dysbiosis emerged as a key player that may influence cancer development, treatment, and prognosis through diverse biological processes. Metastatic BC has a highly variable clinical course, and more recently, immune checkpoint inhibitors (ICIs) have become an emerging therapy in BC. Even with standardised treatment protocols, patients do not respond similarly, reflecting each individual´s heterogeneity, unique BC features, and tumour microenvironment. However, there is insufficient data regarding predictive factors of response to available treatments for BC. The microbiota could be a crucial piece of the puzzle to anticipate better individual BC risk and prognosis, pharmacokinetics, pharmacodynamics, and clinical efficacy. In recent years, it has been shown that gut microbiota may modulate cancer treatments’ efficacy and adverse effects, and it is also apparent that both cancer itself and anticancer therapies interact with gut microbiota bidirectionally. Moreover, it has been proposed that certain gut microbes may protect the host against inappropriate inflammation and modulate the immune response. Future clinical research will determine if microbiota may be a prognostic and predictive factor of response to ICI and/or its side effects. Also, modulation of microbiota can be used to improve outcomes in BC patients. In this review, we discuss the potential implications of metabolomics and pharmacomicrobiomics that might impact BC immunotherapy treatment.

5 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MVMarina Vitorino
Marina Vitorino
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
TCTelma Caleça
Telma Caleça
CSCatarina Santos
Catarina Santos
The tumour microenvironment (TME) comprises a complex ecosystem of different cell types, including immune cells, cells of the vasculature and lymphatic system, cancer-associated fibroblasts, pericytes, and adipocytes. Cancer proliferation, invasion, metastasis, drug resistance and immune escape are all influenced by the dynamic interaction between cancer cells and TME. Microbes, such as bacteria, fungi, viruses, archaea and protists, found within tumour tissues, constitute the intratumour microbiota, which is tumour type-specific and distinct among patients with different clinical outcomes. Growing evidence reveals a significant relevance of local microbiota in the colon, liver, breast, lung, oral cavity and pancreas carcinogenesis. Moreover, there is a growing interest in the tumour immune microenvironment (TIME) pointed out in several cross-sectional studies on the correlation between microbiota and TME. It is now known that microorganisms have the capacity to change the density and function of anticancer and suppressive immune cells, enabling the promotion of an inflammatory environment. As immunotherapy (such as immune checkpoint inhibitors) is becoming a promising therapy using TIME as a therapeutic target, the analysis and comprehension of local microbiota and its modulating strategies can help improve cancer treatments.

25 April 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MCMargarida Carrolo
Margarida Carrolo
JMJoão A. I. Miranda
João A. I. Miranda
GVGuilherme Vilhais
Guilherme Vilhais
AQAntónio Quintela
António Quintela
MSMário Fontes e Sousa
Mário Fontes e Sousa
FPFrancisco R. Pinto
Francisco R. Pinto
Organotropism has been known since 1889, yet this vital component of metastasis has predominantly stayed elusive. This mini-review gives an overview of the current understanding of the underlying mechanisms of organotropism and metastases development by focusing on the formation of the pre-metastatic niche, immune defenses against metastases, and genomic alterations associated with organotropism. The particular case of brain metastases is also addressed, as well as the impact of organotropism in cancer therapy. The limited comprehension of the factors behind organotropism underscores the necessity for efficient strategies and treatments to manage metastases.

1 July 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
MSMafalda Sampaio-Alves
Mafalda Sampaio-Alves
ENEduardo Netto
Eduardo Netto
GFGonçalo Fernandez
Gonçalo Fernandez
EOEdson Oliveira
Edson Oliveira
CACarla Amaro
Carla Amaro
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. The mainstay of management for GBM is surgical resection, radiation (RT), and chemotherapy (CT). Even with optimized multimodal treatment, GBM has a high recurrence and poor survival rates ranging from 12 to 24 months in most patients. Recently, relevant advances in understanding GBM pathophysiology have opened new avenues for therapies for recurrent and newly diagnosed diseases. GBM's hypoxic microenvironment has been shown to be highly associated with aggressive biology and resistance to RT and CT. Hyperbaric oxygen therapy (HBOT) may increase anticancer therapy sensitivity by increasing oxygen tension within the hypoxic regions of the neoplastic tissue. Previous data have investigated HBOT in combination with cytostatic compounds, with an improvement of neoplastic tissue oxygenation, inhibition of HIF-1α activity, and a significant reduction in the proliferation of GBM cells. The biological effect of ionizing radiation has been reported to be higher when it is delivered under well-oxygenated rather than anoxic conditions. Several hypoxia-targeting strategies reported that HBOT showed the most significant effect that could potentially improve RT outcomes, with higher response rates and survival and no serious adverse events. However, further prospective and randomized studies are necessary to validate HBOT's effectiveness in the ‘real world' GBM clinical practice.